Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
Yue Yang, Xing-Fu Li, Xiao Zhang, et al.
Rheumatology and Therapy (2020) Vol. 7, Iss. 4, pp. 851-866
Open Access | Times Cited: 20

Showing 20 citing articles:

JAK inhibitors for rheumatoid arthritis
Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 4, pp. 333-344
Closed Access | Times Cited: 43
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
Peter C. Taylor, Cedric Laedermann, Rieke Alten, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4527-4527
Open Access | Times Cited: 23
Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies
Chrysoula G. Gialouri, Savvina Moustafa, Κonstantinos Thomas, et al.
Rheumatology International (2023) Vol. 43, Iss. 3, pp. 421-435
Open Access | Times Cited: 19
The mosaic of autoimmunity – Finally discussing in person. The 13th international congress on autoimmunity 2022 (AUTO13) Athens
Naim Mahroum, Abdulrahman Elsalti, Abdulkarim Alwani, et al.
Autoimmunity Reviews (2022) Vol. 21, Iss. 10, pp. 103166-103166
Open Access | Times Cited: 20
Efficacy of Janus kinase inhibitors in rheumatoid arthritis
Camille Langbour, Jessica René, Philippe Goupille, et al.
Inflammation Research (2023) Vol. 72, Iss. 5, pp. 1121-1132
Closed Access | Times Cited: 8
Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
Chanyuan Wu, Qian Wang, Jian Shi, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 6, pp. 1609-1622
Open Access | Times Cited: 4
Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study
Yue Yang, Jingyang Li, Ju Liu, et al.
The Lancet Regional Health - Western Pacific (2023), pp. 100925-100925
Open Access | Times Cited: 3
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND
Désirée van der Heijde, Cynthia E. Kartman, Li Xie, et al.
The Journal of Rheumatology (2021) Vol. 49, Iss. 2, pp. 133-141
Open Access | Times Cited: 7
Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE
Zhanguo Li, Jiankang Hu, Xiang-Pei Li, et al.
Advances in Therapy (2020) Vol. 38, Iss. 1, pp. 772-781
Closed Access | Times Cited: 5
REAL-LIFE DATA IN RHEUMATOID ARTHRITIS PATIENTS USING BARICITINIB AT A SINGLE CENTER
Betül Ergün, Adem Küçük
Rheumatology Quarterly (2024) Vol. 2, Iss. 1, pp. 15-18
Open Access
Novel and potential future therapeutic options in Sjögren's syndrome
Ting Zhao, Runrun Zhang, Zhaofu Li, et al.
Heliyon (2024) Vol. 10, Iss. 19, pp. e38803-e38803
Open Access
Safety and Efficacy of Baricitinib, Upadacitinib, and Sarilumab Implementation in Moderately-to-Severely Active Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Current Evidence
Giannis Meziridis, Polytimi Sidiropoulou, Chrysa Pourzitaki, et al.
Cureus (2024)
Open Access
Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis
Penélope Esther Palominos, Ilka Benedet Lineburger, Ricardo Machado Xavier
Expert Opinion on Emerging Drugs (2021) Vol. 26, Iss. 3, pp. 303-321
Closed Access | Times Cited: 3
Rheumatoid arthritis and DVT risk
Susan L. Quisenberry, Phillip T. Atchison, Damon B. Cottrell
Nursing (2022) Vol. 52, Iss. 2, pp. 49-53
Closed Access | Times Cited: 2
JAK Inhibitors in Rheumatoid Arthritis
Kathryn Biddle, Jonathan P. E. White, Nidhi Sofat
EMJ Allergy & Immunology (2022)
Open Access | Times Cited: 1
Infectious side effects of baricitinib: A big data analysis based on VigiBase
Naim Mahroum, Mehmet Fatih Ozkan, Tunahan Abali, et al.
Autoimmunity Reviews (2022) Vol. 22, Iss. 1, pp. 103215-103215
Open Access | Times Cited: 1
Atypical clinical presentation of rheumatoid arthritis
Ksenija Bošković, Aleksandra Savic, Biljana Erdeljan, et al.
Srpski arhiv za celokupno lekarstvo (2023) Vol. 151, Iss. 9-10, pp. 583-586
Open Access
Medicinal Attributes of Heterocyclic Compounds in Rheumatoid Arthritis: Recent Developments and SAR Studies
Vikram Jeet Singh, Bharti Sharma, Pooja A. Chawla
Current Topics in Medicinal Chemistry (2022) Vol. 22, Iss. 22, pp. 1821-1846
Closed Access
Janus kinase inhibitors in patients with ankylosing spondylitis: Great news, but some concerns on cardiovascular disease risk still exist. Author's reply
Shu Li, Fen Li, Ni Mao, et al.
European Journal of Internal Medicine (2022) Vol. 103, pp. 109-110
Closed Access
Efficacy and safety of different doses of baricitinib for rheumatoid arthritis: A Bayesian network meta-analysis
Hai-Kun Wang, Na Wu, Su Dan
Medicine (2022) Vol. 101, Iss. 38, pp. e30676-e30676
Open Access
Page 1

Scroll to top